Donald L. Lamm, MD, FACS, presented “BCG Failure: Defining Failure and Managing Difficult Cases of Non-Muscle Invasive Bladder Cancer” during the 28th Annual Perspectives in Urology: Point Counterpoint on November 16, 2019 in Scottsdale, Arizona.
How to cite: Lamm, Donald L. “BCG Failure: Defining Failure and Managing Difficult Cases of Non-Muscle Invasive Bladder Cancer” November 16, 2019. Accessed Apr 2024. https://dev.grandroundsinurology.com/bcg-failure-defining-failure-and-managing-difficult-cases-of-non-muscle-invasive-bladder-cancer/
BCG Failure: Defining Failure and Managing Difficult Cases of Non-Muscle Invasive Bladder Cancer – Summary:
Donald L. Lamm, MD, FACS, Director of BCG Oncology and Clinical Professor of Surgery at the University of Arizona College of Medicine, discusses the criteria required of studies looking for alternative drug therapies to Bacillus Calmette-Guerin (BCG) to treat non-muscle invasive bladder cancer (NMIBC). Because there are many BCG refractory, recurrent, intolerant, and unresponsive patients, and because there is a global shortage of BCG, new drugs are much needed. To get funding, studies will require FDA approval, and Dr. Lamm suggests that researchers are more likely to receive approval quickly by using standard definitions and providing clear follow-up and end-points in their proposals.
About Perspectives in Urology: Point Counterpoint
Perspectives in Urology: Point Counterpoint (PCP) is an annual, multi-day, CME-accredited conference devoted to discussing and debating the latest topics in men’s health and general urology, as well as management of bladder, renal, and both localized and advanced prostate cancer. More than didactic lectures, the conference’s format includes debates, point-counterpoint discussion panels, and unique case-based presentations. Dr. Uzzo presented this lecture during the 28th PCP in 2019. Please visit this page in order to register for future PCP meetings or view our collection page for more educational lectures from this conference.
